mirtazapine has been researched along with Anxiety Neuroses in 35 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD)." | 9.51 | A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. ( Erickson, CA; Keary, CJ; Mathieu-Frasier, L; McDougle, CJ; Mullett, JE; Palumbo, ML; Politte, LC; Posey, DJ; Ravichandran, CT; Stigler, KA; Thom, RP, 2022) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 7.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 7.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 6.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD)." | 5.51 | A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. ( Erickson, CA; Keary, CJ; Mathieu-Frasier, L; McDougle, CJ; Mullett, JE; Palumbo, ML; Politte, LC; Posey, DJ; Ravichandran, CT; Stigler, KA; Thom, RP, 2022) |
| "This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms." | 5.13 | Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. ( Akbiyik, DI; Alkis, N; Cankurtaran, ES; Ozalp, E; Soygur, H; Turhan, L, 2008) |
| "Mirtazapine was administered to 10 patients with DSM-IV major depressive disorder and comorbid GAD in an 8-week open-label study." | 5.09 | Mirtazapine in major depression with comorbid generalized anxiety disorder. ( DeVane, CL; Freund, BV; Goodnick, PJ; Puig, A, 1999) |
| "The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs)." | 5.09 | A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. ( Guenin, KD; Kohn, AE; McDougle, CJ; Posey, DJ; Swiezy, NB, 2001) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 3.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| "Pancreatitis can be a rare but serious side-effect of Mirtazapine." | 3.74 | Mirtazapine associated with recurrent pancreatitis - a case report. ( Burke, J; Hussain, A, 2008) |
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "A total of 60 MDD patients with a score above 18 on the Hamilton Anxiety Rating Scale (HARS) were randomly assigned to 8 weeks of fixed dosing treatment with mirtazapine (15-30 mg/day) and paroxetine (10-20 mg/day)." | 2.76 | Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. ( Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ, 2011) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 2.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with a novel mode of action that differs from other antidepressants that are currently available." | 2.40 | Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. ( Nutt, DJ, 1998) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (20.00) | 18.2507 |
| 2000's | 12 (34.29) | 29.6817 |
| 2010's | 11 (31.43) | 24.3611 |
| 2020's | 5 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| McDougle, CJ | 2 |
| Thom, RP | 1 |
| Ravichandran, CT | 1 |
| Palumbo, ML | 1 |
| Politte, LC | 1 |
| Mullett, JE | 1 |
| Keary, CJ | 1 |
| Erickson, CA | 1 |
| Stigler, KA | 1 |
| Mathieu-Frasier, L | 1 |
| Posey, DJ | 2 |
| Šakić, B | 1 |
| Greš, A | 1 |
| Gajić, Z | 1 |
| Ozdemir, F | 1 |
| Dural, E | 1 |
| Baskak, NS | 1 |
| Kır, Y | 1 |
| Baskak, B | 1 |
| Suzen, HS | 1 |
| Rifkin-Zybutz, R | 1 |
| MacNeill, S | 1 |
| Davies, SJ | 1 |
| Dickens, C | 1 |
| Campbell, J | 1 |
| Anderson, IM | 1 |
| Chew-Graham, CA | 1 |
| Peters, TJ | 1 |
| Lewis, G | 1 |
| Wiles, N | 1 |
| Kessler, D | 1 |
| Haddad, PM | 1 |
| Al Abdulla, M | 1 |
| Latoo, J | 1 |
| Iqbal, Y | 1 |
| Gray, E | 1 |
| Chen, T | 1 |
| Menzel, J | 1 |
| Schwartz, T | 1 |
| Kaye, WH | 1 |
| Jaffe, RJ | 2 |
| Juneja, NS | 2 |
| Coffey, BJ | 1 |
| Hairston, DR | 1 |
| de Similien, RH | 1 |
| Himelhoch, S | 1 |
| Forrester, A | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 2 |
| Luther, JF | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 1 |
| Chou, WH | 1 |
| Lin, FS | 1 |
| Lin, CP | 1 |
| Lin, WY | 1 |
| Yie, JC | 1 |
| Sun, WZ | 1 |
| Sokolover, N | 1 |
| Merlob, P | 1 |
| Klinger, G | 1 |
| Khan, AY | 1 |
| Golewale, MH | 1 |
| Kahn, DA | 1 |
| Klein, DN | 1 |
| Arnow, BA | 1 |
| Barkin, JL | 1 |
| Dowling, F | 1 |
| Kocsis, JH | 1 |
| Leon, AC | 1 |
| Manber, R | 1 |
| Rothbaum, BO | 1 |
| Croom, KF | 1 |
| Perry, CM | 1 |
| Plosker, GL | 1 |
| Sukul, YR | 1 |
| Birkenhäger, TK | 1 |
| van den Broek, WW | 1 |
| Mulder, PG | 1 |
| Bruijn, JA | 1 |
| Schutters, SI | 2 |
| Van Megen, HJ | 2 |
| Van Veen, JF | 2 |
| Denys, DA | 1 |
| Westenberg, HG | 2 |
| Kim, JE | 1 |
| Yoon, SJ | 1 |
| Kim, J | 1 |
| Jung, JY | 1 |
| Jeong, HS | 1 |
| Cho, HB | 1 |
| Shin, E | 1 |
| Lyoo, IK | 1 |
| Kim, TS | 1 |
| Egashira, N | 1 |
| Shirakawa, A | 1 |
| Abe, M | 1 |
| Niki, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Estabrook, KR | 1 |
| Pheister, M | 1 |
| Lenze, EJ | 1 |
| Schruers, KR | 1 |
| Gambi, F | 1 |
| De Berardis, D | 1 |
| Campanella, D | 1 |
| Carano, A | 1 |
| Sepede, G | 1 |
| Salini, G | 1 |
| Mezzano, D | 1 |
| Cicconetti, A | 1 |
| Penna, L | 1 |
| Salerno, RM | 1 |
| Ferro, FM | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Fusar-Poli, P | 1 |
| Matteo, L | 1 |
| Luca, de M | 1 |
| Politi, P | 1 |
| Cortesi, M | 1 |
| Carboni, V | 1 |
| Vaishnavi, S | 1 |
| Connor, K | 1 |
| Davidson, JR | 1 |
| Hussain, A | 1 |
| Burke, J | 1 |
| Cankurtaran, ES | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Akbiyik, DI | 1 |
| Turhan, L | 1 |
| Alkis, N | 1 |
| Pinder, RM | 1 |
| Nutt, DJ | 2 |
| Farah, A | 1 |
| Falkai, P | 1 |
| Goodnick, PJ | 1 |
| Puig, A | 1 |
| DeVane, CL | 1 |
| Freund, BV | 1 |
| Leinonen, E | 1 |
| Skarstein, J | 1 |
| Behnke, K | 1 |
| Agren, H | 1 |
| Helsdingen, JT | 1 |
| Guenin, KD | 1 |
| Kohn, AE | 1 |
| Swiezy, NB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders[NCT01302964] | Phase 3 | 30 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312] | 402 participants (Anticipated) | Interventional | 2022-07-30 | Active, not recruiting | |||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Pediatric Anxiety Rating Scale (PARS) is a clinician-rated instrument that assesses anxiety symptoms that are commonly associated with social anxiety, separation anxiety, and generalized anxiety disorders. Scaled score ranges form 0-25 with higher scores indicating more severe anxiety symptoms. Means were estimated using a repeated measures linear regression model with treatment group, study week (in categories), and their interaction as covariates, and assuming a common mean between treatment groups at baseline. Confidence intervals reflect a Bonferroni multiple testing correction accounting for the selection of two primary outcomes. (NCT01302964)
Timeframe: Weeks Baseline, 2, 4, 6, and 10
| Intervention | score on a scale (Mean) |
|---|---|
| Mirtazapine | -4.9 |
| Placebo | -3.2 |
The Clinical Global Impressions Global Improvement (CGI-I) is designed to take into account all factors to arrive at an assessment of response to treatment. The CGI-I scale ranges from 1 to 7 (1=very much improved; 2= much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse), with lower scores indicating improvement (1=very much improved and 2=much improved). In this study the CGI was focused on the target symptom of anxiety. Participants with a CGI-I score of 1 or 2 were classified as responders. The CGI-I was administered biweekly for 6 weeks and again at 10 weeks during the study. The participant who withdrew from the study before 10 weeks was not included in the calculations. (NCT01302964)
Timeframe: Screen (Visit 1) Baseline (Visit 2) and Endpoint (Week 10)
| Intervention | Proportion of participants (Number) |
|---|---|
| Mirtazapine | 0.47 |
| Placebo | 0.20 |
4 reviews available for mirtazapine and Anxiety Neuroses
| Article | Year |
|---|---|
Mirtazapine: a review of its use in major depression and other psychiatric disorders.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Databases, Bibliographic; Depressive Disorder, | 2009 |
Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials a | 1998 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
12 trials available for mirtazapine and Anxiety Neuroses
| Article | Year |
|---|---|
A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder.
Topics: Adolescent; Anxiety; Anxiety Disorders; Autism Spectrum Disorder; Child; Child, Preschool; Double-Bl | 2022 |
Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.
Topics: Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Comorbidity; Data Interpretation, Statistical; | 2020 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Double-Blind Method; F | 2010 |
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxie | 2011 |
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Anxiety Disorders; Double-Blind Method; Drug Therapy, Combinati | 2011 |
Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Constipation; Female; Humans; | 2005 |
Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.
Topics: Adaptation, Psychological; Adjustment Disorders; Adrenergic alpha-Antagonists; Adult; Antidepressive | 2008 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluox | 1999 |
Mirtazapine in major depression with comorbid generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Comorbidity; Depressive Disorder; Drug A | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Autist | 2001 |
19 other studies available for mirtazapine and Anxiety Neuroses
| Article | Year |
|---|---|
Mirtazapine-Induced Hyponatremia in a Patient with Systemic Mastocytosis and Generalized Anxiety Disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Humans; Hyponatremia; Mastocytosis, Systemic; M | 2023 |
The Association of
Topics: Adult; Anxiety Disorders; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Genotype; Hum | 2020 |
Brief psychotic disorder associated with quarantine and mild COVID-19.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; COVID-19; Humans; Lorazepam; Ma | 2020 |
Mirtazapine and Weight Gain in Avoidant and Restrictive Food Intake Disorder.
Topics: Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Child; Feeding and Eating Disorders; Fe | 2018 |
Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety | 2018 |
Treatment of phantom shocks: A case report.
Topics: Antidepressive Agents; Anxiety Disorders; Cocaine-Related Disorders; Defibrillators, Implantable; De | 2019 |
Mirtazapine, in orodispersible form, for patients with preoperative psychological distress: A pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Female; Human | 2016 |
Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Body Temperature Regulation; Female; Fol | 2008 |
A case of chronic drug-induced neutropenia.
Topics: Anti-Anxiety Agents; Anti-Infective Agents; Anxiety Disorders; Chronic Disease; Female; Humans; Metr | 2008 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi | 2009 |
Trait anxiety and defensive functioning in relation to antidepressant treatment outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Female; Huma | 2009 |
N-acetyl-L-cysteine inhibits marble-burying behavior in mice.
Topics: Acetylcysteine; alpha-Tocopherol; Animals; Antipsychotic Agents; Anxiety Disorders; Behavior, Animal | 2012 |
A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone.
Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disor | 2012 |
Reversal of SSRI-associated urinary retention with mirtazapine augmentation.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety | 2012 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord | 2007 |
Mirtazapine associated with recurrent pancreatitis - a case report.
Topics: Abdominal Pain; Adult; Amylases; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Dis | 2008 |
The pharmacologic rationale for the clinical use of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; | 1997 |